KENNESAW, GA / ACCESSWIRE / December 11, 2017 / XCELL BIOLOGIX™, a private company focused on commercializing innovative regenerative medicine technologies, today announced that it has entered into an exclusive worldwide license agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM), part of Wake Forest School of Medicine, for development and commercialization of its novel amnion derived product candidates that accelerate wound closure and re-epithelialization for the protection, healing and repair of chronic wounds and severe burns.
"We are excited about this collaboration with a world-class, innovative research and development institute. WFIRM's technology will allow us to address an unmet need in the global $8.5B advanced wound care and $0.5B dermal substitute markets," said XCELL BIOLOGIX President and CEO, Bruce Anderson. "Many of these patients are diabetics who have chronic wounds that are difficult to heal."
Anderson said the ability to apply a powder, hydrogel or spray derived from amnion membrane to fill irregular or deep wounds could be a game-changing technology platform for some patients because of the potential reduction in cost and lack of availability of larger diameter sheets or patches."
"We are delighted to be working with XCELL BIOLOGIX and through this agreement, we will be moving the technology forward so that it can benefit patients," said Anthony Atala, M.D., Director of WFIRM. "That is the ultimate goal of our research and the field of regenerative medicine."
Preclinical results demonstrate that XCELL product candidates with solubilized amnion membrane (SAM) Technology™ can offer superior results to the current clinical standard of care for the closure of full thickness dermal wounds.
The company will initially manufacture a multi-product candidate platform of amnion derived powder, hydrogel and aerosol products, resulting in effective ready-to-use products that are easy to produce, store and apply to wounds to accelerate wound closure and re-epithelialization of severe burns. The company plans to file for regulatory approvals of its product candidates in the United States and Europe in 2018.
Media Contact: Bruce Anderson, email@example.com, 678-879-3580
About XCELL BIOLOGIX
XCELL BIOLOGIX, LLC, is a global regenerative medicine company focused on innovative human stem cell based technologies that could disrupt traditional painful and expensive treatment options for tissue regeneration and healing of chronic wounds and severe burns. The company is rapidly building a portfolio of unique patented regenerative treatment product candidates to improve patients' outcomes along with reducing pain and lowering costs. The company was founded in 2015 by Bruce Anderson and Steve Anderson of Kennesaw, Georgia, and Longboat Key, Florida, respectively, who bring more than 70 years' global experience developing, manufacturing, processing and commercializing more than 20 implantable human cardiovascular and orthopedic tissues and Class II and III medical devices. XCell Biologix was formed in Florida and is headquartered in suburban Atlanta, Georgia. For more information, please visit the company's website at www.xcellbiologix.com.
Established in 2004 as part of Wake Forest School of Medicine in Winston-Salem, NC, the 450-member Institute was the first regenerative medicine institute established with primary-appointed, multi-disciplinary faculty under one roof. Scientists at the Institute were the first in the world to create a laboratory-grown organ that was successfully implanted in patients. To date, the Institute and its research teams are working to develop cell therapies and replacement tissues and organs for more than 40 different areas of the body.
Safe Harbor Statement
This press release contains certain forward-looking statements. Statements that are not historical facts, including statements about our perspectives and expectations, are forward-looking statements. The words "expect," "believe," "estimate," "intend," "plan" and similar expressions, when related to the company, indicate forward-looking statements. An example includes the statement regarding our plan to file for regulatory approval of our products in the United States and Europe in 2018. These statements reflect our current view and are subject to various risks and uncertainties, including, but not limited to, the inherent uncertainties associated with the process of obtaining regulatory approval to market product candidates and the commercialization of products that have received regulatory approval. Excessive reliance should not be placed on those statements. Forward-looking statements relate only to the date they were made, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date they were made.
SOURCE: XCELL BIOLOGIX